NCT02960087View on ClinicalTrials.gov

Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

April 30, 2029

Study Completion Date

October 30, 2029

Conditions
Prostate Carcinoma
Interventions
RADIATION

Low dose rate brachytherapy

I-125 to a total dose of 144 Gy

RADIATION

High dose rate brachytherapy

27 Gy in 2 fractions

Trial Locations (7)

N6A 5W9

London Health Sciences Centre Research Inc., London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

The Jewish General Hospital, Montreal

G1R 2J6

Hotel-Dieu de Quebec, Québec

All Listed Sponsors
lead

Canadian Cancer Trials Group

NETWORK

NCT02960087 - Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer | Biotech Hunter | Biotech Hunter